Study S000578

Efficacy and Safety of Mazdutide in Adults With Prediabetes: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial (DREAM-PRE)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07654062
Acronym: DREAM-PRE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 150
Start: 2026-07
Primary completion: 2028-06
Lead sponsor: Shandong Provincial Hospital
Conditions: Prediabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance (Prediabetes)
Interventions: DRUG:Mazdutide; DRUG:Placebo; BEHAVIORAL:Standardized Lifestyle Intervention
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:SWYX:NO. 2026-1026

Registered primary outcomes

Proportion of Participants Achieving Normal Glucose Regulation (NGR) at Week 24 [Week 24]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0005838	Mazdutide versus placebo in Chinese adults with type 2 diabetes. Zhu D, Nature	2026	Randomized trial	PMID 41407859 DOI	registry reference BACKGROUND:41407859
R0007335	Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Guo L, Nature	2026	Randomized trial	PMID 41407860 DOI	registry reference BACKGROUND:41407860
R0012443	Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Zhang B, Diabetes care	2024	Randomized trial	PMID 37943529 DOI	registry reference BACKGROUND:37943529
R0018858	Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Kahn SE, Diabetes care	2024	Randomized trial	PMID 38907683 DOI	registry reference BACKGROUND:38907683
R0016107	A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Ji L, Nature communications	2023	Randomized trial	PMID 38092790 DOI	registry reference BACKGROUND:38092790
R0023399	Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH, The New England journal of medicine	2021	Randomized trial	PMID 33567185 DOI	registry reference BACKGROUND:33567185
R0022927	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Pi-Sunyer X, The New England journal of medicine	2015	Randomized trial	PMID 26132939 DOI	registry reference BACKGROUND:26132939